Results 1 to 10 of about 29,283 (148)

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance

open access: goldJournal of the Pakistan Medical Association, 2023
Objectives: To find out the prevalence of CYP2C19*2 genetic polymorphism in ischemic heart disease patients, and to determine its relation with clopidogrel resistance in different genotype groups. Method: The cross-sectional study was conducted from August 2015 to December 2019 at the Army Medical College, National University of Medical Sciences ...
Usman, Nawaz   +2 more
semanticscholar   +5 more sources

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi‐physiologic population pharmacokinetic approach [PDF]

open access: yesClinical and Translational Science
Proguanil, an antimalarial drug, undergoes hepatic uptake by the polymorphic organic cation transporter 1 (OCT1) and is subsequently metabolized by the cytochrome P‐450 2C19 (CYP2C19) enzyme into its active metabolite, cycloguanil.
Juyoung Khwarg   +5 more
doaj   +3 more sources

Association between low body weight and cytochrome P‐450 enzyme activity in patients with anorexia nervosa

open access: yesPharmacology Research & Perspectives, 2020
Very little is known to which extent severe underweight could affect cytochrome P‐450 (CYP) enzyme activity. In this study, 24 patients with anorexia nervosa at two occasions ingested single oral doses of five test drugs known to be metabolized by CYP1A2,
Pål Sandvik   +3 more
doaj   +2 more sources

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics

open access: yesFrontiers in Pharmacology, 2022
Clinical practice environments without in-house pharmacogenetic testing often rely on commercial laboratories, especially in the setting of pharmacogenetic testing intended to guide psychotropic use.
Christopher Blazy   +3 more
doaj   +1 more source

Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping [PDF]

open access: yesJournal of Stroke, 2017
Background and Purpose To compare the efficacy and safety of antiplatelet agents for the secondary prevention of ischemic stroke based on cytochrome P450 2C19 (CYP2C19) polymorphisms.
Sang Won Han   +20 more
doaj   +1 more source

Antiplatelet therapy de-escalation in a patient after percutaneous coronary intervention with a high risk of bleeding

open access: yesРоссийский кардиологический журнал, 2023
According to recommendations of ESC 2020-year, de-escalation of therapy with a P2Y12 receptor inhibitor (transition from prasugrel or ticagrelor to clopidogrel) It can be considered as an alternative strategy of dual antiplatelet therapy (DAPT) for ...
A. A. Kassymova   +3 more
doaj   +1 more source

Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel

open access: yesPlatelets, 2021
In the setting of coronary heart diseases (CHDs) on treatment with clopidogrel, ADP-induced platelet aggregation has been demonstrated with ischemic events.
Huaibin Wan   +5 more
doaj   +1 more source

The interactions between COVID-19 drugs and psychotropic agents

open access: yesEuropean Psychiatry, 2021
Coronavirus disease (COVID-19) is a systemic infection targeting multiple organs. Interstitial pneumonia is the landmark feature of this condition. Severe acute respiratory symptoms requiring intensive care support arises for about one out of twenty ...
C. Hiemke
doaj   +1 more source

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

open access: yesBMC Pharmacology and Toxicology, 2020
Background Clopidogrel is an inactive prodrug, it catalyzed into its active form by Cytochrome 450 and Paraoxonase-1(PON-1). polymorphisms of genes encoding these enzymes will affect the efficacy of Clopidogrel.
Zhaowei Zhang   +3 more
doaj   +1 more source

Cytochrome p-450 polymorphisms and response to clopidogrel.

open access: yesNew England Journal of Medicine, 2009
BACKGROUND Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.
J. Mega   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy